◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Axsome Therapeutics Inc (AXSM) EBITDA 2013–TTM

Name: Axsome Therapeutics Inc (AXSM) ebitda history 2013-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Axsome Therapeutics Inc annual ebitda for fiscal 2025 was -$168 million, an increase of 38.5% from -$273 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

AXSM Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
EBITDA	—	($168M)	($273M)	($225M)	($175M)	($124M)	($100M)	($67M)	($33M)	($28M)	($28M)	($9M)	($3M)	($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AXSM Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($61M)	($25M)	($44M)	($43M)	($55M)	($71M)	($61M)	($76M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

HALO EBITDA — Halozyme Therapeutics Inc
BMRN EBITDA — Biomarin Pharmaceutical Inc
MDGL EBITDA — Madrigal Pharmaceuticals Inc
CORT EBITDA — Corcept Therapeutics Incorporated
APGE EBITDA — Apogee Therapeutics, Inc. Common Stock
KRYS EBITDA — Krystal Biotech Inc

More AXSM metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All AXSM financial statements → Interactive AXSM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.